BioNTech SE Sponsored ADR $BNTX Shares Acquired by Victory Capital Management Inc.

Key Points

• Victory Capital Management boosted its BioNTech stake by 97.0%, adding 203,700 shares to hold 413,685 shares (about 0.18% of the company) worth $37,531,000 at quarter-end.
• Other large investors — including Dodge & Cox (new ~$93.4M stake), Vontobel, Allianz, Lingohr and LBP AM — also increased positions, leaving institutional ownership at 15.52%.
• Analysts maintain a "Moderate Buy" consensus (11 Buys, 4 Holds, 1 Sell) with a consensus target of $140.10, while the stock trades near $101.50 with a market cap of $22.86B and a 12‑month range of $81.20–$124.00.

Victory Capital Management Inc. increased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 97.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 413,685 shares of the company's stock after acquiring an additional 203,700 shares during the quarter. Victory Capital Management Inc. owned approximately 0.18% of BioNTech worth $37,531,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of BNTX. Vontobel Holding Ltd. grew its holdings in shares of BioNTech by 17.9% during the third quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company's stock valued at $7,110,000 after purchasing an additional 10,924 shares during the last quarter. Allianz SE lifted its holdings in shares of BioNTech by 635.0% in the 2nd quarter. Allianz SE now owns 5,880 shares of the company's stock worth $626,000 after purchasing an additional 5,080 shares during the last quarter. Dodge & Cox bought a new stake in shares of BioNTech in the 2nd quarter worth approximately $93,421,000. Lingohr Asset Management GmbH increased its position in BioNTech by 598.4% in the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company's stock worth $4,699,000 after buying an additional 40,821 shares during the period. Finally, LBP AM SA lifted its stake in BioNTech by 15.7% in the third quarter. LBP AM SA now owns 353,329 shares of the company's stock valued at $34,845,000 after buying an additional 47,859 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Trading Down 0.4%

Shares of NASDAQ:BNTX opened at $101.50 on Friday. The company has a 50 day moving average of $106.82 and a 200-day moving average of $103.14. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The firm has a market cap of $22.86 billion, a P/E ratio of -38.59 and a beta of 1.51. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $124.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group reissued a "buy" rating and set a $151.00 price target on shares of BioNTech in a report on Wednesday, December 3rd. Berenberg Bank reiterated a "buy" rating on shares of BioNTech in a research report on Friday, January 23rd. UBS Group raised shares of BioNTech to a "hold" rating in a research note on Thursday, December 4th. The Goldman Sachs Group upgraded shares of BioNTech from a "neutral" rating to a "buy" rating and upped their target price for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Finally, HC Wainwright restated a "buy" rating and issued a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $140.10.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.